1 unknown. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Unknown 1 |
Follow Indolent B-cell Lymphomas: new trials by email Literature Review of Indolent B-cell Lymphomas trials Research Report on Indolent B-cell Lymphomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Ibrutinib - Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas | Phase 3 | Unknown | The University of Hong Kong | 62 | 2016-11-01 | 2018-04-12 |
Hepatitis B, Chronic (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Waldenstrom Macroglobulinemia (1)
Blood Protein Disorders (1) · Blood-Borne Infections (1) · Cardiovascular Diseases (1) · Chronic Disease (1) · Communicable Diseases (1) · DNA Virus Infections (1) · Digestive System Diseases (1) · Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Hepadnaviridae Infections (1) · Hepatitis (1) · Hepatitis B (1)
ibrutinib (1)
The University of Hong Kong (1)
Hong Kong (1)